Cantor Fitzgerald analyst Prakhar Agrawal downgraded Provention Bio (PRVB) to Neutral from Overweight with a price target of $25, up from $16, after Sanofi (SNY) agreed to acquire Provention Bio for $25 per share in cash, representing an equity value of approximately $2.9B.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on PRVB:
- Provention Bio cancels Q4, FY22 earnings release, conference call
- Provention Bio Soars after Acquisition by Sanofi for $2.9 Billion
- Sanofi acquires Provention Bio for $25 per share or $2.9B
- Provention Bio management to meet virtually with Oppenheimer
- Provention Bio price target lowered to $16 from $18 at H.C. Wainwright